Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 893

1.

Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Mitri ZI, Parmar S, Johnson B, Kolodzie A, Keck JM, Morris M, Guimaraes AR, Beckett BR, Borate U, Lopez CD, Kemmer KA, Alumkal JJ, Beer TM, Corless CL, Mills GB, Gray JW, Bergan RC.

J Transl Med. 2018 Dec 14;16(1):358. doi: 10.1186/s12967-018-1733-y.

2.

Significant Excess of Electronlike Events in the MiniBooNE Short-Baseline Neutrino Experiment.

Aguilar-Arevalo AA, Brown BC, Bugel L, Cheng G, Conrad JM, Cooper RL, Dharmapalan R, Diaz A, Djurcic Z, Finley DA, Ford R, Garcia FG, Garvey GT, Grange J, Huang EC, Huelsnitz W, Ignarra C, Johnson RA, Karagiorgi G, Katori T, Kobilarcik T, Louis WC, Mariani C, Marsh W, Mills GB, Mirabal J, Monroe J, Moore CD, Mousseau J, Nienaber P, Nowak J, Osmanov B, Pavlovic Z, Perevalov D, Ray H, Roe BP, Russell AD, Shaevitz MH, Spitz J, Stancu I, Tayloe R, Thornton RT, Tzanov M, Van de Water RG, White DH, Wickremasinghe DA, Zimmerman ED; MiniBooNE Collaboration.

Phys Rev Lett. 2018 Nov 30;121(22):221801. doi: 10.1103/PhysRevLett.121.221801.

PMID:
30547637
3.

Cooperative effect of oncogenic MET and PIK3CA in an HGF-dominant environment in breast cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2018 Dec 5. pii: molcanther.0710.2018. doi: 10.1158/1535-7163.MCT-18-0710. [Epub ahead of print]

PMID:
30518672
4.

PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness.

Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.

Cancer Res. 2018 Nov 27. pii: canres.1003.2018. doi: 10.1158/0008-5472.CAN-18-1003. [Epub ahead of print]

PMID:
30482774
5.

PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.

Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, Krakstad C, Beroukhim R, Salvesen HB.

Clin Cancer Res. 2018 Nov 15. doi: 10.1158/1078-0432.CCR-18-0452. [Epub ahead of print]

PMID:
30442683
6.

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.

Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, Leonard PG, Hua X, Vellano CP, Woessner R, Sahni N, Scott KL, Mills GB.

Nat Commun. 2018 Nov 2;9(1):4583. doi: 10.1038/s41467-018-06949-w.

7.

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.

Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H.

Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001.

8.

The chromatin accessibility landscape of primary human cancers.

Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW, Satpathy AT, Mumbach MR, Hoadley KA, Robertson AG, Sheffield NC, Felau I, Castro MAA, Berman BP, Staudt LM, Zenklusen JC, Laird PW, Curtis C; Cancer Genome Atlas Analysis Network, Greenleaf WJ, Chang HY.

Science. 2018 Oct 26;362(6413). pii: eaav1898. doi: 10.1126/science.aav1898.

PMID:
30361341
9.

State-of-the-art strategies for targeting the DNA damage response in cancer.

Pilié PG, Tang C, Mills GB, Yap TA.

Nat Rev Clin Oncol. 2018 Oct 24. doi: 10.1038/s41571-018-0114-z. [Epub ahead of print] Review.

PMID:
30356138
10.

Molecular determinants of post-mastectomy breast cancer recurrence.

Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F.

NPJ Breast Cancer. 2018 Oct 12;4:34. doi: 10.1038/s41523-018-0089-z. eCollection 2018.

11.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Dec;8(12):1548-1565. doi: 10.1158/2159-8290.CD-18-0804. Epub 2018 Oct 15.

PMID:
30322867
12.

Personalized Integrated Network Modeling of the Cancer Proteome Atlas.

Ha MJ, Banerjee S, Akbani R, Liang H, Mills GB, Do KA, Baladandayuthapani V.

Sci Rep. 2018 Oct 8;8(1):14924. doi: 10.1038/s41598-018-32682-x.

13.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

14.

Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery.

Hsieh HJ, Zhang W, Lin SH, Yang WH, Wang JZ, Shen J, Zhang Y, Lu Y, Wang H, Yu J, Mills GB, Peng G.

Nat Commun. 2018 Sep 28;9(1):3982. doi: 10.1038/s41467-018-05639-x.

15.

Modulation of the Hippo pathway and organ growth by RNA processing proteins.

Mach J, Atkins M, Gajewski KM, Mottier-Pavie V, Sansores-Garcia L, Xie J, Mills RA, Kowalczyk W, Van Huffel L, Mills GB, Halder G.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10684-10689. doi: 10.1073/pnas.1807325115. Epub 2018 Sep 26.

PMID:
30257938
16.

RNA editing derived epitopes function as cancer antigens to elicit immune responses.

Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, Talukder A, Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P.

Nat Commun. 2018 Sep 25;9(1):3919. doi: 10.1038/s41467-018-06405-9.

17.

Author Correction: Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin.

Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH, Lee HY.

Exp Mol Med. 2018 Sep 19;50(9):124. doi: 10.1038/s12276-018-0148-4.

18.

Author Correction: Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer.

Kang MH, Choi H, Oshima M, Cheong JH, Kim S, Lee JH, Park YS, Choi HS, Kweon MN, Pack CG, Lee JS, Mills GB, Myung SJ, Park YY.

Nat Commun. 2018 Aug 31;9(1):3599. doi: 10.1038/s41467-018-06061-z.

19.

MERIT: Systematic analysis and characterization of Mutational Effect on RNA Interactome Topology.

Li Y, McGrail DJ, Xu J, Li J, Liu NN, Sun M, Lin R, Pancsa R, Zhang J, Lee JS, Wang H, Mills GB, Li X, Yi S, Sahni N.

Hepatology. 2018 Aug 28. doi: 10.1002/hep.30242. [Epub ahead of print]

PMID:
30153342
20.

Comprehensive Characterization of Cancer Driver Genes and Mutations.

Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L.

Cell. 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034. No abstract available.

21.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. No abstract available.

PMID:
30096301
22.

Targeting gamma secretase: has progress moved up a Notch?

Ileana Dumbrava EE, Mills GB, Yap TA.

Ann Oncol. 2018 Sep 1;29(9):1889-1891. doi: 10.1093/annonc/mdy307. No abstract available.

PMID:
30084907
23.

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.

Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; Cancer Genome Atlas Research Network, Rätsch G.

Cancer Cell. 2018 Aug 13;34(2):211-224.e6. doi: 10.1016/j.ccell.2018.07.001. Epub 2018 Aug 2.

24.

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.

Rhyasen GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB, Chen H.

PLoS One. 2018 Jul 23;13(7):e0200826. doi: 10.1371/journal.pone.0200826. eCollection 2018.

25.

Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.

Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00245. Epub 2018 Apr 25.

26.

In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.

Grzeskowiak CL, Kundu ST, Mo X, Ivanov AA, Zagorodna O, Lu H, Chapple RH, Tsang YH, Moreno D, Mosqueda M, Eterovic K, Fradette JJ, Ahmad S, Chen F, Chong Z, Chen K, Creighton CJ, Fu H, Mills GB, Gibbons DL, Scott KL.

Nat Commun. 2018 Jul 16;9(1):2732. doi: 10.1038/s41467-018-04572-3.

27.

AKT isoform-specific expression and activation across cancer lineages.

Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S, Ng PK, Li Y, Yu Q, Lu Y, Jeong KJ, Chen X, Gao M, Liang J, Li W, Tian X, Jonasch E, Mills GB, Ding Z.

BMC Cancer. 2018 Jul 16;18(1):742. doi: 10.1186/s12885-018-4654-5.

28.

Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.

Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM.

Clin Cancer Res. 2018 Oct 1;24(19):4874-4886. doi: 10.1158/1078-0432.CCR-17-3697. Epub 2018 Jun 29.

PMID:
29959144
29.

Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation.

Li Y, McGrail DJ, Xu J, Mills GB, Sahni N, Yi S.

Trends Biochem Sci. 2018 Aug;43(8):576-592. doi: 10.1016/j.tibs.2018.05.002. Epub 2018 Jun 22. Review.

PMID:
29941230
30.

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.

Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT, Rathmell WK, Linehan WM.

Cell Rep. 2018 Jun 19;23(12):3698. doi: 10.1016/j.celrep.2018.06.032. No abstract available.

31.

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Antony J, Zanini E, Kelly Z, Tan TZ, Karali E, Alomary M, Jung Y, Nixon K, Cunnea P, Fotopoulou C, Paterson A, Roy-Nawathe S, Mills GB, Huang RY, Thiery JP, Gabra H, Recchi C.

EMBO Rep. 2018 Aug;19(8). pii: e45670. doi: 10.15252/embr.201745670. Epub 2018 Jun 15.

PMID:
29907679
32.

Integrated Molecular Characterization of Testicular Germ Cell Tumors.

Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM; Cancer Genome Atlas Research Network, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA.

Cell Rep. 2018 Jun 12;23(11):3392-3406. doi: 10.1016/j.celrep.2018.05.039.

33.

β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer.

Lee H, Kim N, Yoo YJ, Kim H, Jeong E, Choi S, Moon SU, Oh SH, Mills GB, Yoon S, Kim WY.

Oncogene. 2018 Oct;37(40):5466-5475. doi: 10.1038/s41388-018-0362-5. Epub 2018 Jun 12.

PMID:
29895971
34.

Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p.

Kuppa SS, Jia W, Liu S, Nguyen H, Smyth SS, Mills GB, Dobbin KK, Hardman WJ, Murph MM.

Cancer Lett. 2018 Sep 28;432:84-92. doi: 10.1016/j.canlet.2018.05.037. Epub 2018 May 31.

PMID:
29859298
35.

Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance.

Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, Deraedt T, Cichowski K, Welm AL, Mori Y, Mills GB, Brugge JS.

Cancer Cell. 2018 Jun 11;33(6):985-1003.e7. doi: 10.1016/j.ccell.2018.05.001. Epub 2018 May 24.

PMID:
29805077
36.

Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype.

McGrail DJ, Lin CC, Dai H, Mo W, Li Y, Stephan C, Davies P, Lu Z, Mills GB, Lee JS, Lin SY.

Cell Rep. 2018 May 15;23(7):2095-2106. doi: 10.1016/j.celrep.2018.04.068.

37.

Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer.

Kang MH, Choi H, Oshima M, Cheong JH, Kim S, Lee JH, Park YS, Choi HS, Kweon MN, Pack CG, Lee JS, Mills GB, Myung SJ, Park YY.

Nat Commun. 2018 May 15;9(1):1920. doi: 10.1038/s41467-018-04244-2. Erratum in: Nat Commun. 2018 Aug 31;9(1):3599.

38.

Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo.

Parekh A, Das S, Parida S, Das CK, Dutta D, Mallick SK, Wu PH, Kumar BNP, Bharti R, Dey G, Banerjee K, Rajput S, Bharadwaj D, Pal I, Dey KK, Rajesh Y, Jena BC, Biswas A, Banik P, Pradhan AK, Das SK, Das AK, Dhara S, Fisher PB, Wirtz D, Mills GB, Mandal M.

Oncogene. 2018 Aug;37(33):4546-4561. doi: 10.1038/s41388-018-0272-6. Epub 2018 May 10.

PMID:
29743594
39.

Cancer driver mutation prediction through Bayesian integration of multi-omic data.

Wang Z, Ng KS, Chen T, Kim TB, Wang F, Shaw K, Scott KL, Meric-Bernstam F, Mills GB, Chen K.

PLoS One. 2018 May 8;13(5):e0196939. doi: 10.1371/journal.pone.0196939. eCollection 2018.

40.

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.

Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G.

Nat Med. 2018 May;24(5):556-562. doi: 10.1038/s41591-018-0012-z. Epub 2018 May 7.

41.

Predicting high-risk endometrioid carcinomas using proteins.

Du D, Ma W, Yates MS, Chen T, Lu KH, Lu Y, Weinstein JN, Broaddus RR, Mills GB, Liu Y.

Oncotarget. 2018 Apr 13;9(28):19704-19715. doi: 10.18632/oncotarget.24803. eCollection 2018 Apr 13.

42.

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.

Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS.

Nat Commun. 2018 May 3;9(1):1777. doi: 10.1038/s41467-018-04179-8.

43.

Credentialing Individual Samples for Proteogenomic Analysis.

Zhao W, Li J, Akbani R, Liang H, Mills GB.

Mol Cell Proteomics. 2018 Aug;17(8):1515-1530. doi: 10.1074/mcp.RA118.000645. Epub 2018 May 1.

PMID:
29716986
44.

A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer.

Peng X, Xu X, Wang Y, Hawke DH, Yu S, Han L, Zhou Z, Mojumdar K, Jeong KJ, Labrie M, Tsang YH, Zhang M, Lu Y, Hwu P, Scott KL, Liang H, Mills GB.

Cancer Cell. 2018 May 14;33(5):817-828.e7. doi: 10.1016/j.ccell.2018.03.026. Epub 2018 Apr 26.

PMID:
29706454
45.

First Measurement of Monoenergetic Muon Neutrino Charged Current Interactions.

Aguilar-Arevalo AA, Brown BC, Bugel L, Cheng G, Church ED, Conrad JM, Cooper RL, Dharmapalan R, Djurcic Z, Finley DA, Fitzpatrick RS, Ford R, Garcia FG, Garvey GT, Grange J, Huelsnitz W, Ignarra C, Imlay R, Johnson RA, Jordan JR, Karagiorgi G, Katori T, Kobilarcik T, Louis WC, Mahn K, Mariani C, Marsh W, Mills GB, Mirabal J, Moore CD, Mousseau J, Nienaber P, Osmanov B, Pavlovic Z, Perevalov D, Ray H, Roe BP, Russell AD, Shaevitz MH, Spitz J, Stancu I, Tayloe R, Thornton RT, Van de Water RG, Wascko MO, White DH, Wickremasinghe DA, Zeller GP, Zimmerman ED; MiniBooNE Collaboration.

Phys Rev Lett. 2018 Apr 6;120(14):141802. doi: 10.1103/PhysRevLett.120.141802.

46.

EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation.

Lee JH, Liu R, Li J, Wang Y, Tan L, Li XJ, Qian X, Zhang C, Xia Y, Xu D, Guo W, Ding Z, Du L, Zheng Y, Chen Q, Lorenzi PL, Mills GB, Jiang T, Lu Z.

Mol Cell. 2018 Apr 19;70(2):197-210.e7. doi: 10.1016/j.molcel.2018.03.018.

PMID:
29677490
47.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 May;10(5). pii: e8446. doi: 10.15252/emmm.201708446.

48.

BRD4 facilitates replication stress-induced DNA damage response.

Zhang J, Dulak AM, Hattersley MM, Willis BS, Nikkilä J, Wang A, Lau A, Reimer C, Zinda M, Fawell SE, Mills GB, Chen H.

Oncogene. 2018 Jul;37(28):3763-3777. doi: 10.1038/s41388-018-0194-3. Epub 2018 Apr 11.

PMID:
29636547
49.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L.

Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5.

50.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; Cancer Genome Atlas Research Network, Hu H.

Cell. 2018 Apr 5;173(2):400-416.e11. doi: 10.1016/j.cell.2018.02.052.

Supplemental Content

Loading ...
Support Center